Detalhe da pesquisa
1.
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
J Oncol Pharm Pract;
29(5): 1172-1177, 2023 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36067063
2.
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide.
Oncologist;
27(9): 718-e694, 2022 09 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35640474
3.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Lancet;
395(10218): 132-141, 2020 01 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31836199
4.
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
BMC Cancer;
21(1): 659, 2021 Jun 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34078314
5.
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
JAMA;
310(8): 804-11, 2013 Aug 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23982366
6.
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).
Prostate Cancer Prostatic Dis;
25(4): 735-740, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35079115
7.
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors.
Cancer Chemother Pharmacol;
86(4): 475-486, 2020 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32897402
8.
Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.
J Pharm Biomed Anal;
181: 113073, 2020 Mar 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31927166